Abingdon Health PLC Notice of Results
11 Marzo 2024 - 9:53AM
RNS Regulatory News
RNS Number : 3301G
Abingdon Health PLC
11 March 2024
Abingdon Health plc
("Abingdon Health"
or "the Company")
Notice of
Results
York, U.K. 11 March 2024: Abingdon Health plc (AIM: ABDX), a
leading international lateral flow contract research (CRO) and
contract development and manufacturing organisation (CDMO),
announces that its interim results for the six
months ended 31 December 2023 will be released on 14 March
2024.
Enquiries
|
Abingdon Health plc
|
www.abingdonhealth.com/investors/
|
|
Chris Yates, Chief Executive Officer
|
Via
Walbrook PR
|
|
Chris Hand, Non-Executive Chairman
|
|
|
|
|
|
Singer Capital Markets (Sole Broker and Nominated
Adviser)
|
Tel: +44
(0)20 7496 3000
|
|
Peter Steel, Alex Bond, Jalini
Kalaravy (Corporate Finance)
|
|
|
Tom Salvesen (Corporate
Broking)
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Abingdon
Health plc
Abingdon Health is a leading
lateral flow contract research (CRO) and contract development and
manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers
product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays
or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health aims to support the increase in
need for rapid results across many industries and locations and
produces lateral flow tests in areas such as infectious disease,
clinical testing including companion diagnostics, animal health and
environmental testing. Faster access to results allows for rapid
decision making, targeted intervention and can support better
outcomes.
Abingdon Health's Abingdon Simply
Test™ range of
self-tests is an ecommerce platform that offers a range of
self-tests to empowers consumers to manage their own health and
wellbeing. The Abingdon Simply
Test™ ecommerce
site offers consumers a range of information to support them in
making informed decisions on the tests available. In addition, the
site provides Abingdon's contract services customers with a
potential route to market for self-tests. The Abingdon Simply Test
range is also sold through international distributors and through
other channels in the UK and Ireland such as pharmacy
chains.
Founded in 2008, Abingdon
Health is headquartered in York, England. For more
information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORGIGDXBUBDGSB
Grafico Azioni Abingdon Health (LSE:ABDX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Abingdon Health (LSE:ABDX)
Storico
Da Nov 2023 a Nov 2024
